Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.

Fiche publication

Date publication

juillet 2022

Journal

Journal of cancer research and clinical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ETIENNE-SELLOUM Nelly , Pr FORNECKER Luc-Matthieu

Tous les auteurs :
Claustre G, Boulanger C, Maloisel F, Etienne-Selloum N, Fornecker LM, Durot E, Slimano F, Graff V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35789429

Résumé

Rituximab (R) or obinutuzumab (G) combined with CHOP chemotherapy are used in previously untreated follicular lymphoma (FL). The aim is to compare in real life setting the efficacy and safety of these therapeutic strategies and assess the economic impact of introducing G.